ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Zenox
|
974 |
323K |
13 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
974
|
323K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Zenox
|
974 |
323K |
3 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
974
|
323K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
Zenox
|
4.2K |
3.8M |
7 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
4.2K
|
3.8M
|
7
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Zenox
|
974 |
323K |
4 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
974
|
323K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
Zenox
|
4.2K |
3.8M |
22 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
4.2K
|
3.8M
|
22
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
Zenox
|
4.2K |
3.8M |
0 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
4.2K
|
3.8M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
Zenox
|
4.2K |
3.8M |
9 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
4.2K
|
3.8M
|
9
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Zenox
|
974 |
323K |
21 |
21/08/23 |
21/08/23 |
ASX - By Stock
|
974
|
323K
|
21
|
|
ASX - By Stock
|
PAR |
Re:
PAR. SP
|
|
Zenox
|
974 |
323K |
17 |
19/08/23 |
19/08/23 |
ASX - By Stock
|
974
|
323K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Zenox
|
907 |
283K |
10 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
907
|
283K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Zenox
|
907 |
283K |
1 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
907
|
283K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Zenox
|
907 |
283K |
15 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
907
|
283K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Race Strategic Update August 2023
|
|
Zenox
|
592 |
188K |
8 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
592
|
188K
|
8
|
|
ASX - By Stock
|
RAC |
Re:
Industry news
|
|
Zenox
|
1.7K |
608K |
8 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
1.7K
|
608K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Zenox
|
1.0K |
399K |
14 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
399K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Zenox
|
1.0K |
399K |
20 |
05/08/23 |
05/08/23 |
ASX - By Stock
|
1.0K
|
399K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Zenox
|
1.0K |
399K |
17 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
399K
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Zenox
|
1.0K |
399K |
9 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
1.0K
|
399K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Zenox
|
72 |
26K |
21 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
72
|
26K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Zenox
|
84 |
30K |
8 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
84
|
30K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Study demonstrates Bene PPS is unique
|
|
Zenox
|
40 |
13K |
16 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
40
|
13K
|
16
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
9 |
26/07/23 |
26/07/23 |
ASX - By Stock
|
4.1K
|
1.9M
|
9
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
6 |
24/07/23 |
24/07/23 |
ASX - By Stock
|
4.1K
|
1.9M
|
6
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
10 |
23/07/23 |
23/07/23 |
ASX - By Stock
|
4.1K
|
1.9M
|
10
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
8 |
23/07/23 |
23/07/23 |
ASX - By Stock
|
4.1K
|
1.9M
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Phase 3 Clinical Trial Update
|
|
Zenox
|
47 |
18K |
5 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
47
|
18K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Phase 3 Clinical Trial Update
|
|
Zenox
|
47 |
18K |
0 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
47
|
18K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Phase 3 Clinical Trial Update
|
|
Zenox
|
47 |
18K |
3 |
05/07/23 |
05/07/23 |
ASX - By Stock
|
47
|
18K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR Reports Phase 3 Clinical Trial Update
|
|
Zenox
|
47 |
18K |
7 |
04/07/23 |
04/07/23 |
ASX - By Stock
|
47
|
18K
|
7
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Zenox
|
17K |
6.7M |
11 |
13/06/23 |
13/06/23 |
ASX - By Stock
|
17K
|
6.7M
|
11
|
|
ASX - By Stock
|
PAR |
Re:
Kumagai, one of the Fantastic Four and some Mozz Firsts...
|
|
Zenox
|
51 |
16K |
3 |
02/06/23 |
02/06/23 |
ASX - By Stock
|
51
|
16K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Kumagai, one of the Fantastic Four and some Mozz Firsts...
|
|
Zenox
|
51 |
16K |
7 |
02/06/23 |
02/06/23 |
ASX - By Stock
|
51
|
16K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: iPPS shows 3-year equivalent durability in OA Canine Study
|
|
Zenox
|
44 |
17K |
7 |
02/06/23 |
02/06/23 |
ASX - By Stock
|
44
|
17K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
General OA media and info
|
|
Zenox
|
670 |
255K |
6 |
17/05/23 |
17/05/23 |
ASX - By Stock
|
670
|
255K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Webinar - 6.30am tomorrow
|
|
Zenox
|
77 |
27K |
9 |
03/05/23 |
03/05/23 |
ASX - By Stock
|
77
|
27K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Zenox
|
23 |
9.2K |
7 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
23
|
9.2K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Zenox
|
23 |
9.2K |
6 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
23
|
9.2K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
|
|
Zenox
|
386 |
163K |
9 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
386
|
163K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
PAR and the BML findings
|
|
Zenox
|
31 |
9.9K |
4 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
31
|
9.9K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
PAR and the BML findings
|
|
Zenox
|
31 |
9.9K |
3 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
31
|
9.9K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
PAR and the BML findings
|
|
Zenox
|
31 |
9.9K |
6 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
31
|
9.9K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
|
|
Zenox
|
386 |
163K |
18 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
386
|
163K
|
18
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
7 |
17/04/23 |
17/04/23 |
ASX - By Stock
|
4.1K
|
1.9M
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
|
|
Zenox
|
386 |
163K |
2 |
14/04/23 |
14/04/23 |
ASX - By Stock
|
386
|
163K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
PAR Broker Data
|
|
Zenox
|
336 |
146K |
2 |
13/04/23 |
13/04/23 |
ASX - By Stock
|
336
|
146K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
PAR Broker Data
|
|
Zenox
|
336 |
146K |
2 |
13/04/23 |
13/04/23 |
ASX - By Stock
|
336
|
146K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
The P Value Primer
|
|
Zenox
|
13 |
6.1K |
13 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
13
|
6.1K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
|
|
Zenox
|
386 |
163K |
11 |
11/04/23 |
11/04/23 |
ASX - By Stock
|
386
|
163K
|
11
|
|
ASX - By Stock
|
PAR |
Re:
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
|
|
Zenox
|
386 |
163K |
6 |
08/04/23 |
08/04/23 |
ASX - By Stock
|
386
|
163K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
Ann: iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
|
|
Zenox
|
386 |
163K |
10 |
08/04/23 |
08/04/23 |
ASX - By Stock
|
386
|
163K
|
10
|
|